Gut. 2009 Oct; 58(10): 1427-36
Sokol H, Beaugerie L
The venture of lymphoproliferative disorders (LDs) has become a major anxiety for clinicians managing patients with inflammatory viscus disease (IBD). Yet it is difficult to characterize the doable domain of immunosuppressive therapy from the background venture cod to the inflammatory disorder itself. LDs are clonal B or T radiophone proliferation display considerable nonuniformity and the incidence has accumulated since the 1970s. The strongest and best-established venture factors for LDs are direct and acquired immunodeficiency (HIV, immunosuppressant), notably via defective insusceptible surveillance of Epstein-Barr virus. In some auto-immune diseases (eg, Sjögren's syndrome), inflammatory diseases (eg, rheumatoid arthritis) or habitual suppuration (chronic pyothorax), the venture of LD is increased. In IBD patients, in general, the venture of LD seems to be kindred to or very slightly higher than in the generalized population. The role of immunosuppressants in lymphomagenesis is difficult to individualise because another factors potentially participating are inter-linked. Concordant data declare that thiopurine therapy is associated with a moderately accumulated venture of LD. Data regarding immunosuppressant are tight and become from diseases another than IBD but the venture seems low. Data regarding venture of LD in IBD patients receiving anti-tumour necrosis bourgeois alpha (TNFalpha) agents are insufficient at this time, mainly because most of the patients are co-treated with thiopurines. The recently individualised risks of hepatosplenic T radiophone lymphoma and fatal post-mononucleosis LD, in young phallic patients with IBD who are co-treated with anti-TNFalpha and thiopurines, and EBV-seronegative IBD males, respectively, are belike low but remain to be better quantified.
